ISBT 128 implementation plan for cellular therapy products

Paul Ashford, Pat Distler, Adrian Gee, Alan Lankester, Stella Larsson, Irene Feller, Kathy Loper, Derwood Pamphilon, Leigh Poston, Fran Rabe, Ineke Slaper-Cortenbach, Zbigniew Szczepiorkowski, Phyllis Warkentin

Research output: Contribution to journalReview article

6 Scopus citations

Abstract

The publication of new standards for terminology and labeling marks an important step in ensuring consistency and traceability of cellular therapies at the global level. However, it is only with the widespread implementation of the standard that the benefits can be truly realized. This paper provides guidance on the practical aspects of adopting these new standards for organizations with differing current levels of computerization. It discusses project management, equipment, licensing, and validation topics.

Original languageEnglish (US)
Pages (from-to)258-264
Number of pages7
JournalJournal of Clinical Apheresis
Volume22
Issue number5
DOIs
StatePublished - Nov 1 2007

    Fingerprint

Keywords

  • Coding
  • ISBT 128
  • Implementation
  • Labeling
  • Terminology

ASJC Scopus subject areas

  • Hematology

Cite this

Ashford, P., Distler, P., Gee, A., Lankester, A., Larsson, S., Feller, I., Loper, K., Pamphilon, D., Poston, L., Rabe, F., Slaper-Cortenbach, I., Szczepiorkowski, Z., & Warkentin, P. (2007). ISBT 128 implementation plan for cellular therapy products. Journal of Clinical Apheresis, 22(5), 258-264. https://doi.org/10.1002/jca.20146